Platelet activation in the hypertensive disorders of pregnancy

Sunil Nadar, Gregory Lip

Research output: Contribution to journalArticle

17 Citations (Scopus)


The hypertensive disorders of pregnancy, including gestational hypertension, pre-eclampsia and eclampsia, continue to be an important cause of maternal morbidity and mortality. Abnormal placentation is considered to be the main instigating factor, which then leads to widespread maternal endothelial activation and dysfunction. This endothelial perturbation leads to the release of many substances into the circulation, many of which result in platelet activation. For example, there is an imbalance between the levels of prostacyclin (a vasodilator and platelet inhibitor) and thromboxane (a platelet activator and vasoconstrictor), which then results in the maintenance of high blood pressure and complications. It is also likely that platelets play an important part in the pathogenesis of hypertension in pregnancy. The use of antiplatelet drugs has been shown to be effective in reducing the incidence of gestational hypertension in women at high risk and in preventing the complications associated with it. In addition, some antihypertensive agents are effective in reversing platelet activation in essential hypertension and, therefore, their use in pregnancy-induced hypertension may be beneficial in more ways than simply blood pressure reduction.
Original languageEnglish
Pages (from-to)523-9
Number of pages7
JournalExpert opinion on investigational drugs
Issue number5
Publication statusPublished - 1 May 2004


  • platelet activation
  • platelets
  • pregnancy-induced hypertension


Dive into the research topics of 'Platelet activation in the hypertensive disorders of pregnancy'. Together they form a unique fingerprint.

Cite this